At a glance
ClinicalIndex Comparison RecordStandardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
A Phase II Study of AZD4547 for Previously Treated FGFR-Positive Patients With Stage IV Squamous Cell Lung Cancer (Lung-Map Sub-Study)
In Brief
A Phase 3 clinical trial evaluating Docetaxel, FGFR Inhibitor AZD4547, and 1 other intervention for FGFR1 Gene Amplification and 7 related conditions. Completed, enrolled 43 participants across 1,084 sites in 2 countries.
Detailed Summary
This phase II/III trial studies how well FGFR inhibitor AZD4547 (AZD4547) works in treating patients with stage IV squamous cell lung cancer that has come back after previous treatment. This is a sub-study that includes all screened patients positive for the fibroblast growth factor receptor (FGFR) biomarker. FGFR can cause tumor cells to grow more quickly. AZD4547 may decrease the activity of FGFR and may be able to shrink tumors.
Study Details
Timeline
Interventions
Given IV
Given PO
Correlative studies